379 related articles for article (PubMed ID: 26637512)
1. Ceftolozane-tazobactam: A new-generation cephalosporin.
Cluck D; Lewis P; Stayer B; Spivey J; Moorman J
Am J Health Syst Pharm; 2015 Dec; 72(24):2135-46. PubMed ID: 26637512
[TBL] [Abstract][Full Text] [Related]
2. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.
Zhanel GG; Chung P; Adam H; Zelenitsky S; Denisuik A; Schweizer F; Lagacé-Wiens PR; Rubinstein E; Gin AS; Walkty A; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2014 Jan; 74(1):31-51. PubMed ID: 24352909
[TBL] [Abstract][Full Text] [Related]
3. Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.
Cho JC; Fiorenza MA; Estrada SJ
Pharmacotherapy; 2015 Jul; 35(7):701-15. PubMed ID: 26133315
[TBL] [Abstract][Full Text] [Related]
4. Ceftolozane/Tazobactam: A New Cephalosporin and β-Lactamase Inhibitor Combination.
Sucher AJ; Chahine EB; Cogan P; Fete M
Ann Pharmacother; 2015 Sep; 49(9):1046-56. PubMed ID: 26160970
[TBL] [Abstract][Full Text] [Related]
5. In vitro pharmacodynamic evaluation of ceftolozane/tazobactam against β-lactamase-producing Escherichia coli in a hollow-fibre infection model.
Soon RL; Lenhard JR; Bulman ZP; Holden PN; Kelchlin P; Steenbergen JN; Friedrich LV; Forrest A; Tsuji BT
Int J Antimicrob Agents; 2017 Jan; 49(1):25-30. PubMed ID: 27931793
[TBL] [Abstract][Full Text] [Related]
6. Ceftolozane/tazobactam for the treatment of complicated urinary tract and intra-abdominal infections.
Bassetti M; Righi E
Future Microbiol; 2015; 10(2):151-60. PubMed ID: 25689527
[TBL] [Abstract][Full Text] [Related]
7. Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).
Solomkin J; Hershberger E; Miller B; Popejoy M; Friedland I; Steenbergen J; Yoon M; Collins S; Yuan G; Barie PS; Eckmann C
Clin Infect Dis; 2015 May; 60(10):1462-71. PubMed ID: 25670823
[TBL] [Abstract][Full Text] [Related]
8. Ceftolozane/Tazobactam: A Review in Complicated Intra-Abdominal and Urinary Tract Infections.
Scott LJ
Drugs; 2016 Feb; 76(2):231-42. PubMed ID: 26746849
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials.
Popejoy MW; Paterson DL; Cloutier D; Huntington JA; Miller B; Bliss CA; Steenbergen JN; Hershberger E; Umeh O; Kaye KS
J Antimicrob Chemother; 2017 Jan; 72(1):268-272. PubMed ID: 27707990
[TBL] [Abstract][Full Text] [Related]
10. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK
Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
[TBL] [Abstract][Full Text] [Related]
11. Successful Use of Ceftolozane-Tazobactam to Treat a Pulmonary Exacerbation of Cystic Fibrosis Caused by Multidrug-Resistant Pseudomonas aeruginosa.
Vickery SB; McClain D; Wargo KA
Pharmacotherapy; 2016 Oct; 36(10):e154-e159. PubMed ID: 27522066
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model.
Gómez-Junyent J; Benavent E; Sierra Y; El Haj C; Soldevila L; Torrejón B; Rigo-Bonnin R; Tubau F; Ariza J; Murillo O
Int J Antimicrob Agents; 2019 May; 53(5):612-619. PubMed ID: 30682497
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
Sader HS; Farrell DJ; Castanheira M; Flamm RK; Jones RN
J Antimicrob Chemother; 2014 Oct; 69(10):2713-22. PubMed ID: 24917579
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection.
MacGowan AP; Noel AR; Tomaselli SG; Nicholls D; Bowker KE
Antimicrob Agents Chemother; 2016 Jan; 60(1):515-21. PubMed ID: 26552975
[TBL] [Abstract][Full Text] [Related]
15. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012).
Sader HS; Farrell DJ; Flamm RK; Jones RN
J Infect; 2014 Sep; 69(3):266-77. PubMed ID: 24780763
[TBL] [Abstract][Full Text] [Related]
16. Ceftolozane/tazobactam for the treatment of complicated intra-abdominal infections.
Eckmann C; Solomkin J
Expert Opin Pharmacother; 2015 Feb; 16(2):271-80. PubMed ID: 25529765
[TBL] [Abstract][Full Text] [Related]
17. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
[TBL] [Abstract][Full Text] [Related]
18. Antibacterial effect of ceftolozane/tazobactam in combination with amikacin against aerobic Gram-negative bacilli studied in an in vitro pharmacokinetic model of infection.
Noel AR; Bowker KE; Attwood M; MacGowan AP
J Antimicrob Chemother; 2018 Sep; 73(9):2411-2417. PubMed ID: 30020472
[TBL] [Abstract][Full Text] [Related]
19. Ceftolozane/Tazobactam (Zerbaxa)--a new intravenous antibiotic.
Med Lett Drugs Ther; 2015 Mar; 57(1463):31-3. PubMed ID: 25719997
[No Abstract] [Full Text] [Related]
20. Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam-β-Lactamase Inhibitor Combinations.
Soon RL; Lenhard JR; Bulman ZP; Holden PN; Kelchlin P; Steenbergen JN; Friedrich LV; Forrest A; Tsuji BT
Antimicrob Agents Chemother; 2016 Apr; 60(4):1967-73. PubMed ID: 26729494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]